CBIO: Key 2027 data from global oncology trials will drive phase III plans and registration strategies
A robust oncology pipeline is advancing, with key data from global trials of a PD-1/VEGF bispecific and ADCs expected in 2027. Strategic partnerships, efficient trial design, and a strong cash position support rapid progression toward phase III studies and potential registration paths.Based on Cres…